Media - Synox Therapeutics

Skip to content

Life with TGCT
Emactuzumab
About
Media

Expanded Access

Home
Life with TGCT
Emactuzumab
Who we are
Meet the team
Contact
Join us
Events
Publications
Press Releases
Expanded Access
Privacy Policy
Terms & Conditions

Home
Media

Events

CTOS Annual Meeting
18-21 November in Seoul

Browse all Events

Publications

TANGENT study design
20 July 2026
Emactuzumab for dTGCT Long-Term Study Results
1 December 2020
Emactuzumab Phase1 dTGCT
13 July 2015

Browse Featured Publications

Press Releases

Tangent Phase 3 TGCT Results
13 April 2026
SynOx Strengthens Board
21 October 2025
Enrollment Finishes Early
5 August 2025
TGCT Therapy Fast-Tracked
14 April 2025
SynOx Appoints Chair
1 April 2025
SynOx Expands Leadership Team
7 November 2024

Browse all Press Releases

Life with TGCT
Emactuzumab
Who we are
Meet the team
Contact
Join us
Events

Publications
Press Releases
Expanded Access
Terms and Conditions
Privacy Policy

SynOx Therapeutics is a clinical-stage company focused on developing emactuzumab, an investigational, next-generation monoclonal antibody targeting CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.

© Copyright 2026 SynOx Therapeutics. All rights reserved.

You are about to leave our website

We are not responsible for the content. Do you want to proceed?